Two of the biggest acquisitions in the industry confirm a trend in pharma M&A: The big players are trawling for opportunities in the rare-disease space.
What a lot of investors are waiting for, I believe, is a sign that business travel has fully bounced back. Leisure travel has safely returned to 2019 levels, whereas business travel continues to trail.
Cable TV May Lose Half of Subscribers by 2030: Jeff Kagan